Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Roche RHHBY announced that it will acquire clinical-stage biopharmaceutical company Poseida Therapeutics, Inc. PSTX for $9 ...
The following is a summary of “Tumor and Blood B Cell Abundance Outperforms Established Immune Checkpoint Blockade Response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback